42nd first announcement 03 10 2011

8/7/2019 42nd first announcement 03 10 2011

1/7

PHILIPPINE HEART ASSOCIATION

1108, 11th Floor East Tower, PSE Centre

Exchange Road, Ortigas Center, Pasig City

Tel. No.: (+632) 470.5525

Fax No.: (+632) 687.7797

E-mail: [email protected]@philheart.org

Website: www.philheart.org


2/7

1

MESSAGE

EUGENE B. REYES, MDChair, Scientific Committee

SATURNINO P. JAVIER, MDChair, Organizing Committee

ELEANOR A. LOPEZ, MDPresident

Every year, the field of Cardiology grows by leaps and

bounds. As knowledge in the discipline accumulates, clinical

applicability and practice patterns are guided throughformulation of guidelines, consensus statements and

recommendations from international and local associations,

experts groups and key opinion leaders. These are quite

essential if standards are to be set for management, research

and training purposes.

Heretofore, validated goals and outcome expectations

dictate on the direct ions we take, the strategies we employ and

the options we choose. Yet, such standards or goals become

meaningless and inappropriate if they are not tempered with

the realities we confront everyday legislation, socio-economic

restrictions, accessibility, unavailability of drug and technology,

among others.

A compleat clinician integrates all these into a cohesive

body of approaches and policies. This annual convention seeks

to focus on all these and more. Welcome and we wish you allan intellectually rewarding scientific activity.

ELEANOR A. LOPEZ, MD

ISABELO V. ONGTENGCO JR., MD

ROMEO B. CRUZANDRE S. KAHN

SATURNINO P. JAVIER, MD

EUGENE B. REYES, MD

JOEL M. ABANILLA, MD

TIMOTHY C. DY, MD

MA. CONSOLACION DOLOR-TORRES, MD

MARIA TERESA B. ABOLA, MD

President

Vice President

VP for FinanceVP for External Affairs

Secretary

Treasurer

Director

Director

Director

Immediate Past President

42nd ANNUAL PHA CONVENTION

ORGANIZING COMMITTEE

SATURNINO P. JAVIER, MD

EUGENE B. REYES, MD

JOEL M. ABANILLA, MD

ISABELO V. ONGTENGCO JR., MD

TIMOTHY C. DY, MD

MA. CONSOLACION DOLOR-TORRES, MD

MARIA TERESA B. ABOLA, MD

PEDRO P. SAN DIEGO JR., MD

ERLYN C. DEMERRE, MD

Over-all Chair

Chair, Scientific Committee

Chair, Sessions Committee

Chair, Registration

Chair, Exhibits & Physical Arrangement

Chair, Socials

Chair, Protocol

Chair, Information Technology

Chair, Publication

OFFICERS 2010-2011


3/7


4/7


5/7


6/7

ABSTRACTABSTRACT PREPARATION INSTRUCTION

1. The abstract must be submitted on the enclosed Abstract Form.

2. The abstract must be contained in the space provided and use a type size no

smaller than 10 point.

3. Type title in Bold using upper and lower case letters and not to exceed 200

words.4. Type complete names of authors (M.D. or other principal degrees not

necessary). List responsible institutions and their respective cities and

provinces

5. Leave a blank line after author(s)/institution(s) and before abstract text.

6. Abstract text should include purpose, methods, results, and conclusions. Do

not include references or credits. Simple tables or graphs may be included if

they fit within the space allowed.

7. Use standard abbreviations. Place special or unusual abbreviations in

parentheses after the full word the first time it appears. A limit of fiveadditional special abbreviations may be used in each abstract.

8. Please avoid printing on lines of abstract box.

9. Deadline for submission of abstracts: on or before March 15, 2011 and the

final manuscripts on or before March 31, 2011

10. Accepted oral abstracts will be presented during a special session the exact

date of which will be announced at a later date. Posters will be presented

during a special poster presentation session and during breaks in the exhibit

hall.

11. Abstract accepted for presentation will be published in the April to June Issue

of the Philippine Journal of Cardiology.

12. Submit the original abstract (unfolded) by first class or overnight mail to:

Philippine Heart Association Secretariat

1108, 11th Floor East Tower, PSE Centre

Exchange Road, Ortigas Center, Pasig City

13. The complete manuscript should be in a Compact Disc (CD) or Digital

Versatile Disc(DVD) and one (1) hardcopy using MS-Word Application.

Author should provide, and identify as , 5-8 keywords or short phrases that

will assist a reseacher in identifying an information material.

14. Indicate the required information on the authors as follows:

NAME OF AUTHOR/S

NAME OF PRESENTOR

INSTITUTION

TEL NO. FAX NO. E-MAIL ADDRESS

98


7/7

FAMILY NAME GIVEN NAME MIDDLE NAME

INSTITUTION/COMPANY

ADDRESS ZIPCODE

TELEPHONE No. FAX No. E-MAIL ADDRESS

PRC No. PMA No.

REGISTRATION FEE

Please check:

ADVANCE REGULAR DAILY

(Until March 30, 2011) (After March 30, 2011)

PHA member* P 1,200 1,500 700**

Non-member 1,400 1,700 700**

Resident 1,000 1,200 700**

Fellow-in-Training 1,000 1,200 700**

Medical Student 1,000 1,200 700**

Nurse/Technician 1,000 1,200 700**

PHA family member 600 700 700**

Exhibitor 600 800 700**

* Annual membership fee is not included in registration fee**Daily registration fee does not include convention kit.

Signature of Registrant Date

11

REGISTRATION FORMABSTRACT CONTENTS

CAPITALIZE ENTIRE ABSTRACT TITLE

Author. Underline only presenting authors name.Institution, City

OBJECTIVES: State main question or study objective(s) or

hypothesis.

DESIGN: Describe study design. Indicate if randomized, blinded

and if temporal direction, retrospective or prospective.

SETTING: Indicate the study setting (hospital, clinic, community).

Also include the level of cl inical care (primary or tertiary); privatepractice or institutional.

PATIENTS/PARTICIPANTS: State selection procedures, entry

criteria and numbers of participants entering and finishing the

study.

INTERVENTIONS, IF ANY: Describe the essential features of an

intervention/exposure, including the method and duration ofadministration.

MAIN OUTCOME MEASURE(S): The primary study outcome

measure should be indicated as planned before the data collection

began.

RESULTS: Describe measurements that are not evident from the

nature of the main results and indicate any blinding. If possible,the results should be accompanied by confidence intervals (most

often the 95% interval) and the exact level of statistical

significance. For comparative studies, confidence intervals should

relate to the differences between groups. Absolute values should

be indicated when risk changes or effect sizes are given.

CONCLUSIONS: State only those conclusions of the study that are

directly supported by data, along with their clinical application

(avoiding generalization) or whether additional study is required

before the information should be used in usual clinical settings.

10

42nd first announcement 03 10 2011

Documents

Transcript of 42nd first announcement 03 10 2011